Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Thiogenesis Therapeutics, Corp. has announced the European Medicines Agency’s acceptance of its Clinical Trial Application for TTI-0102, aimed at treating MELAS, a rare, inherited mitochondrial disorder with no current approved drugs. This marks a significant milestone as the company prepares to launch a Phase 2 trial in the second quarter of 2024, which will assess the efficacy and safety of TTI-0102 in a double-blind study involving 12 patients across France and the Netherlands. The excitement within Thiogenesis is palpable, as TTI-0102, patented in 2021, shows promise as a treatment for those afflicted by MELAS following a successful preliminary study.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue